晚期肺腺癌EGFR突变状态对培美曲塞疗效的影响

被引：6

作者：

张琼

杨哲

戴洪海

王瑜

韩俊庆

机构：

[1] 山东大学附属省立医院肿瘤中心

来源：

中国肿瘤临床 | 2013年 / 40卷 / 22期

关键词：

肺腺癌; 培美曲塞; 化疗; 表皮生长因子受体;

D O I：

暂无

中图分类号：

R734.2 [肺肿瘤];

学科分类号：

100117 [系统生物医学];

摘要：

目的:研究晚期肺腺癌EGFR突变状态对培美曲塞疗效的影响。方法:收集经病理学确诊且有可评价病灶的晚期肺腺癌患者40例,所有病例均有表皮生长因子受体(epidermal growth factor receptor,EGFR)突变状态检测结果,均采用含培美曲塞方案化疗,以总有效率(ORR)、疾病控制率(DCR)、无进展生存期(PFS)为研究终点进行回顾性分析,比较两组间的疗效差异。结果:EGFR野生组和突变组总有效率分别为44.4%(8/18)和31.8%(7/22)(P=0.412),疾病控制率分别为88.9%(16/18)和81.8%(18/22,P=0.673)。EGFR野生组中位PFS较突变组延长(8.9vs.5.3个月,P=0.046)。结论:晚期肺腺癌EGFR突变状态对培美曲塞的疗效有影响。

引用

页码：1378 / 1381

页数：4

共 10 条

[1]

2012年美国临床肿瘤学会晚期非小细胞肺癌内科治疗新进展 [J].

吴国明 .

西部医学, 2012, 24 (09) :1650-1653

[2]

2011年非小细胞肺癌研究进展 [J].

刘雨桃 ;

郏博 ;

石远凯 .

癌症进展, 2012, 10 (02) :124-128+169

[3]

EGFR突变型肺癌的处理 [J].

吴一龙 ;

孙燕 ;

廖美琳 ;

周清华 ;

王长利 ;

陆舜 ;

周彩存 ;

王洁 ;

马胜林 ;

毛伟敏 ;

王俊 ;

许林 ;

傅小龙 ;

宋启斌 ;

朱广迎 ;

程颖 ;

韩宝惠 ;

黄诚 ;

王震 .

循证医学, 2011, 11 (02) :65-68

[4]

Erratum to: Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer[J] Isamu Okamoto;Keisuke Aoe;Terufumi Kato;Yukio Hosomi;Akira Yokoyama;Fumio Imamura;Katsuyuki Kiura;Tomonori Hirashima;Makoto Nishio;Naoyuki Nogami;Hiroaki Okamoto;Hideo Saka;Nobuyuki Yamamoto;Naoto Yoshizuka;Risa Sekiguchi;Kazuhiro Kiyosawa;Kazuhiko Nakagawa;Tomohide Tamura Investigational New Drugs 2013,

[5]

Influence of Chemotherapy on EGFR Mutation Status Among Patients With Non–Small-Cell Lung Cancer[J] Hua Bai;Zhijie Wang;Keneng Chen;Jun Zhao;J. Jack Lee;Shuhang Wang;Qinghua Zhou;Minglei Zhuo;Li Mao;Tongtong An;Jianchun Duan;Lu Yang;Meina Wu;Zhen Liang;Yuyan Wang;Xiaozheng Kang;Jie Wang Journal of Clinical Oncology 2012,

[6]

Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer[J] Ha Yeon Lee;Hee Kyung Ahn;Ji Yun Jeong;Mi Jung Kwon;Jung-Ho Han;Jong-Mu Sun;Jin Seok Ahn;Keunchil Park;Yoon-La Choi;Myung-Ju Ahn Lung Cancer 2012,

[7]

Anaplastic Lymphoma Kinase Translocation: A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer[J] Jeong-Ok Lee;Tae Min Kim;Se-Hoon Lee;Dong-Wan Kim;Soyeon Kim;Yoon-Kyung Jeon;Doo Hyun Chung;Woo-Ho Kim;Young Tae Kim;Seok-Chul Yang;Young Whan Kim;Dae Seog Heo;Yung-Jue Bang Journal of Thoracic Oncology 2011,

[8]

Significance of Thymidylate Synthase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherapy[J] Jong-Mu Sun;Joungho Han;Jin Seok Ahn;Keunchil Park;Myung-Ju Ahn Journal of Thoracic Oncology 2011,

[9]

Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed[J] D. Ross Camidge;Scott A. Kono;Xian Lu;Sonia Okuyama;Anna E. Barón;Ana B. Oton;Angela M. Davies;Marileila Varella-Garcia;Wilbur Franklin;Robert C. Doebele Journal of Thoracic Oncology 2011,

[10]

Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor ( EGFR ) mutations[J] Shang-Gin Wu;Chih-Hsin Yang;Chong-Jen Yu;Jih-Hsiang Lee;Ya-Chieh Hsu;Yih-Leong Chang;Jin-Yuan Shih;Pan-Chyr Yang Lung Cancer 2010,

← 1 →